Tenapanor hydrochloride is a Small Molecule owned by Ardelyx, and is involved in 33 clinical trials, of which 29 were completed, 3 are ongoing, and 1 is planned.

Tenapanor is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium

Tenapanor acts as a NHE3 inhibitor. NHE3 is localized to the apical membrane and play important roles in intestinal Na+ absorption with varying activities in different segments of the gastrointestinal tract. The Na+/H+ exchanger 3 mediates the majority of the NaCl and NaHCO3 absorption in the mammalian ileum. In normal digestive physiology, Inhibition of NHE3 regulation leads to inhibition of Na+ absorption, resulting in decreased water absorption and diarrhea.

The revenue for Tenapanor hydrochloride is expected to reach a total of $770m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tenapanor hydrochloride NPV Report.

Tenapanor hydrochloride is originated and owned by Ardelyx. Kyowa Kirin is the other company associated in development or marketing of Tenapanor hydrochloride.

Tenapanor hydrochloride Overview

Tenapanor hydrochloride (Ibsrela) belongs to 4-phenyltetrahydroisoquinolines. It is formulated as tablets for oral route of administration. Ibsrela is indicated for the treatment of  irritable bowel syndrome with constipation (IBS-C) in adults.

Tenapanor is under development for the treatment of hyperphosphatemia in hemodialysis patients, irritable bowel syndrome and hyperphosphatemia in patients with end-stage renal disease. The drug candidate was also under development for the treatment of chronic kidney disease patients with type 2 diabetes mellitus and albuminuria.

Kyowa Kirin Overview

Kyowa Kirin, a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY352,246 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 17%, compared to an operating margin of 15.9% in FY2020. In FY2021, the company recorded a net margin of 14.9%, compared to a net margin of 14.8% in FY2020. The company reported revenues of JPY98,504 million for the third quarter ended September 2022, an increase of 1% over the previous quarter.

Quick View – Tenapanor hydrochloride

Report Segments
  • Innovator (NME)
Drug Name
  • Tenapanor hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Nutritional Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.